Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS‐CoV‐2

O’Kelly, Brendan; McGettrick, Padraig; Angelov, Daniel; McGinty, Tara; Cotter, Aoife G.; Sheehan, Gerard; Lambert, John S.

doi:10.1111/bjh.16798

Cited by 20 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…O'Kelly et al (37) reported a 22-year-old woman with Hodgkin lymphoma who had been infected with SARS-CoV-2. She had a cough, sore throat, pyrexia, chills, and rig-ors for three days.…”

Section: Clinical Manifestation Of Covid-19 In Hematologic Malignant mentioning

confidence: 99%

“…The main imaging findings in patients with COVID-19 pneumonia included infiltrates in the lower areas, bilaterally, on chest X-rays (37,40). The most characteristic features in CT scans of these patients were white patches called "ground-glass opacity", locating fluids in the lungs with reticular or interlobular septal thickening (41), and bilateral consolidation (a multilobar and subsegmental form) (33,42).…”

Section: Imaging Findingsmentioning

confidence: 99%

“…On admission, broad-spectrum antibacterial agents, such as piperacillin-tazobactam and doxycycline, were prescribed against community-acquired pneumonia in a SARS-CoV-2 swab test. When COVID-19 was confirmed, lopinavir, ritonavir, hydroxychloroquine, azithromycin, and corticosteroids were used to treat the patient (37). Zhang et al (10) reported a 60-year-old man with a history of symp-tomatic multiple myeloma infected with SARS-CoV-2 who received intravenous moxifloxacin and tocilizumab.…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus

Lotfali

Ghasemi

Mardani

et al. 2020

Arch Clin Infect Dis

View full text Add to dashboard Cite

: Since late 2019, when novel coronavirus pneumonia emerged in China and spread worldwide, there has been a need for data concerning the clinical characteristics of infected immunocompromised patients. It has been reported that a significant mortality rate occurs in individuals with underlying comorbidities such as hematologic malignancies. Therefore, it is vital to illustrate the clinical manifestations and outcomes of COVID-19 in these vulnerable patients and identify safe therapeutic strategies. This study reviewed the clinical course, laboratory findings, and risk factors associated with hematologic malignant patients with COVID-19 along with the management and therapeutic regimens.

show abstract

“…O'Kelly et al (37) reported a 22-year-old woman with Hodgkin lymphoma who had been infected with SARS-CoV-2. She had a cough, sore throat, pyrexia, chills, and rig-ors for three days.…”

Section: Clinical Manifestation Of Covid-19 In Hematologic Malignant mentioning

confidence: 99%

Section: Imaging Findingsmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus

Lotfali

Ghasemi

Mardani

et al. 2020

Arch Clin Infect Dis

View full text Add to dashboard Cite

show abstract

“…No significant differences in baseline characteristics were observed between the patients with hematologic malignancies who developed COVID-19 and those who did not. However, COVID-19 appeared to be more severe, and more deaths were reported, in the patients with hematologic malignancies compared to the cohort of healthcare providers who developed Several papers have appeared, by individuals, groups of specialists or under the auspices of scientific societies, to offer an initial description of the clinical presentation of COVID-19 in patients with hematologic malignancies and to advocate for general recommendations of good clinical practice in this pandemic period, for both adult and pediatric patients (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). One interesting case report involved a SARS-CoV-2 infection in a 39-year-old patient with chronic lymphocytic leukemia (CLL) where the clinical and biochemical manifestations of COVID-19 were partly masked by the coexisting CLL (6).…”

Section: Introductionmentioning

confidence: 99%

“…One interesting case report involved a SARS-CoV-2 infection in a 39-year-old patient with chronic lymphocytic leukemia (CLL) where the clinical and biochemical manifestations of COVID-19 were partly masked by the coexisting CLL (6). One letter by the University Hospital of Dublin reported on the positive outcome of a young woman with refractory Hodgkin lymphoma (HL) on pembrolizumab who wasinfected with SARS-CoV-2, required intensive care service without intubation, and was safely discharged from the hospital after 16 days (7). A French group (8) reviewed the data of 25 consecutive adult patients admitted to a Hematology Department in Paris with confirmed COVID-19 infection and at least 10 days of follow-up.…”

Section: Introductionmentioning

confidence: 99%

Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned

Isidori¹,

Leval

Gergis

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The COVID-19 pandemic has created unprecedented hurdles to the delivery of care to patients with cancer. Patients with hematologic malignancies appear to have a greater risk of SARS-CoV-2 infection and severe disease due to myelosuppression and lymphopenia. The first challenge, therefore, is how to continue to deliver effective, curative therapy to vulnerable patients and at the same time avoid exposing them, and their health care teams (HCT), to SARS-CoV-2. An additional challenge is the timely completion of the diagnostic and staging studies required to formulate appropriate treatment plans. Deferred procedures and avoidance of multiple trips to the surgical, diagnostic, and laboratory suites require same day consolidation of all procedures. With laboratory medicine absorbed by the need to deploy large scale COVID-testing, the availability of routine molecular tests is affected. Finally, we are increasingly faced with the challenge of making complex treatment decisions in SARS-CoV-2 positive patients with aggressive but potentially curable blood cancers. When to treat, how to treat, when to wait, how long to wait, how to predict and manage toxicities, and how to avoid compromising cure rates remains unknown. We present an outline of the scientific, medical, and operational challenges posed by the COVID-19 pandemic at selected American and European institutions and offer our current view of the key elements of a response. While the peak of the pandemic may be past us, in the absence of a vaccine risks remain, and our alertness and response to future challenges need to be refined and consolidated.

show abstract